{"schema_version":"secwatch.filing_event.v1","accession":"0001839882-23-030323","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.050639+00:00","generated_at":"2026-06-08T06:25:29.828648+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tonix Q3 net loss $28M ($1.83/shr); cash drops to $6.9M; phase 3 fibromyalgia data due Dec 2023","bullets":["Net product revenue of $4.0M in first quarter after acquiring Zembrace/Tosymra in June 2023.","Cash and equivalents $6.9M at Sep 30, 2023 vs $120.2M at Dec 31, 2022.","Public offerings in Aug and Sep 2023 raised net proceeds of $6.3M and $4.0M respectively.","Topline Phase 3 RESILIENT trial (TNX-102 SL) for fibromyalgia expected late December 2023.","Topline Phase 2 PREVENTION study (TNX-1900) for chronic migraine expected early December 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001839882-23-030323","json":"https://secwatch.observer/filing/0001839882-23-030323.json","markdown":"https://secwatch.observer/filing/0001839882-23-030323.md","text":"https://secwatch.observer/filing/0001839882-23-030323.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000183988223030323/0001839882-23-030323-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000183988223030323/tnxp-8k_110923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:25:29.828648+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f7d2551292e9f3d261de7eb3e15e35308bc3195d","claim":"Tonix Pharmaceuticals Holding Corp. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000183988223030323/0001839882-23-030323-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}